1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Ankylosing Spondylitis Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Ankylosing Spondylitis Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Cimzia
1.4.3 Enbrel
1.4.4 Humira
1.4.5 Remicade
1.4.6 Simponi
1.4.7 Others
1.5 Market by Application
1.5.1 Global Ankylosing Spondylitis Drug Market Share by Application: 2021-2026
1.5.2 Hospitals
1.5.3 Clinics
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Ankylosing Spondylitis Drug Market
1.8.1 Global Ankylosing Spondylitis Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Ankylosing Spondylitis Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Ankylosing Spondylitis Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Ankylosing Spondylitis Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Ankylosing Spondylitis Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Ankylosing Spondylitis Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Ankylosing Spondylitis Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Ankylosing Spondylitis Drug Sales Volume
3.3.1 North America Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Ankylosing Spondylitis Drug Sales Volume
3.4.1 East Asia Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.5.1 Europe Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.6.1 South Asia Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.8.1 Middle East Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.9.1 Africa Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.10.1 Oceania Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.11.1 South America Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Ankylosing Spondylitis Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Ankylosing Spondylitis Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Ankylosing Spondylitis Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Ankylosing Spondylitis Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Ankylosing Spondylitis Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Ankylosing Spondylitis Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Ankylosing Spondylitis Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Ankylosing Spondylitis Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Ankylosing Spondylitis Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Ankylosing Spondylitis Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Ankylosing Spondylitis Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Ankylosing Spondylitis Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Ankylosing Spondylitis Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Ankylosing Spondylitis Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Ankylosing Spondylitis Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Ankylosing Spondylitis Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Ankylosing Spondylitis Drug Consumption Volume by Application (2015-2020)
15.2 Global Ankylosing Spondylitis Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Ankylosing Spondylitis Drug Business
16.1 Amgen
16.1.1 Amgen Company Profile
16.1.2 Amgen Ankylosing Spondylitis Drug Product Specification
16.1.3 Amgen Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Eisai
16.2.1 Eisai Company Profile
16.2.2 Eisai Ankylosing Spondylitis Drug Product Specification
16.2.3 Eisai Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Centocor
16.3.1 Centocor Company Profile
16.3.2 Centocor Ankylosing Spondylitis Drug Product Specification
16.3.3 Centocor Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Wyeth
16.4.1 Wyeth Company Profile
16.4.2 Wyeth Ankylosing Spondylitis Drug Product Specification
16.4.3 Wyeth Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Abbott
16.5.1 Abbott Company Profile
16.5.2 Abbott Ankylosing Spondylitis Drug Product Specification
16.5.3 Abbott Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Takeda
16.6.1 Takeda Company Profile
16.6.2 Takeda Ankylosing Spondylitis Drug Product Specification
16.6.3 Takeda Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Johnson & Johnson
16.7.1 Johnson & Johnson Company Profile
16.7.2 Johnson & Johnson Ankylosing Spondylitis Drug Product Specification
16.7.3 Johnson & Johnson Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Mitsubishi Tanabe
16.8.1 Mitsubishi Tanabe Company Profile
16.8.2 Mitsubishi Tanabe Ankylosing Spondylitis Drug Product Specification
16.8.3 Mitsubishi Tanabe Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Schering-Plough
16.9.1 Schering-Plough Company Profile
16.9.2 Schering-Plough Ankylosing Spondylitis Drug Product Specification
16.9.3 Schering-Plough Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Pfizer
16.10.1 Pfizer Company Profile
16.10.2 Pfizer Ankylosing Spondylitis Drug Product Specification
16.10.3 Pfizer Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Ankylosing Spondylitis Drug Manufacturing Cost Analysis
17.1 Ankylosing Spondylitis Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Ankylosing Spondylitis Drug
17.4 Ankylosing Spondylitis Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Ankylosing Spondylitis Drug Distributors List
18.3 Ankylosing Spondylitis Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Ankylosing Spondylitis Drug (2021-2026)
20.2 Global Forecasted Revenue of Ankylosing Spondylitis Drug (2021-2026)
20.3 Global Forecasted Price of Ankylosing Spondylitis Drug (2015-2026)
20.4 Global Forecasted Production of Ankylosing Spondylitis Drug by Region (2021-2026)
20.4.1 North America Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Ankylosing Spondylitis Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Ankylosing Spondylitis Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.2 East Asia Market Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.3 Europe Market Forecasted Consumption of Ankylosing Spondylitis Drug by Countriy
21.4 South Asia Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.5 Southeast Asia Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.6 Middle East Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.7 Africa Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.8 Oceania Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.9 South America Forecasted Consumption of Ankylosing Spondylitis Drug by Country
21.10 Rest of the world Forecasted Consumption of Ankylosing Spondylitis Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer